Drug Type Fab fragment, Biosimilar |
Synonyms Ranibizumab Biosimilar (Curateq Biologics Pvt Ltd.), 雷珠单抗生物类似药(Curateq Biologics Pvt Ltd.), BP 05 + [2] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Wet Macular Degeneration | Phase 3 | India | 22 May 2024 | |
| Wet Macular Degeneration | Phase 3 | Latvia | 22 May 2024 | |
| Wet Macular Degeneration | Phase 3 | Slovakia | 22 May 2024 | |
| Wet age-related macular degeneration | Phase 3 | India | 26 May 2023 |






